ArticleBMC pulmonary medicine2026
Association between serum perfluoroalkyl substances and COPD risk: population evidence and in vitro validation.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPer- and polyfluoroalkyl substances are characterized by environmental persistence, bioaccumulation potential, and multi-organ toxicity. Given their ubiquitous presence in the environment and human serum, concerns regarding respiratory health risks are growing, particularly due to scarce evidence on environmental etiologies of chronic obstructive pulmonary disease in never-smokers. This study aimed to investigate the mechanistic role of these substances in chronic obstructive pulmonary disease through a population-computational-experimental paradigm, with specific focus on lipid-metabolic mediation.
methodsData from the National Health and Nutrition Examination Survey (2007-2018) were analyzed using weighted quantile sum regression and quantile-based g-computation to assess mixture exposure effects. Mediation analysis was performed to evaluate the triglyceride-glucose index as a metabolic intermediate pathway. Network toxicology and molecular docking analyses were conducted to identify core protein targets. Human bronchial epithelial cells were exposed to perfluorooctanoic acid to validate target gene expression and downstream pathway activation.
resultsMixture exposure showed a significant positive association with chronic obstructive pulmonary disease risk. Perfluorooctanesulfonic acid and perfluorooctanoic acid were the primary toxicity contributors. The association remained robust among never-smokers. The triglyceride-glucose index significantly mediated the exposure-disease relationship (mediation proportion: 6.6%-7.8%). SRC, EGFR, PPARG, and MMP9 were identified as core targets. Experimental validation confirmed that perfluorooctanoic acid altered expression of these targets, activating inflammation and remodeling pathways.
conclusionsThese substances disrupt pulmonary homeostasis through concurrent molecular activation and lipid-metabolic disturbance, evidenced by triglyceride-glucose index mediation. This dual mechanism provides new evidence for chronic obstructive pulmonary disease prevention in never-smokers and identifies potential metabolic intervention targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.